24 June, 2022

HTW publishes guidance on stereotactic ablative radiotherapy (SABR)

Health Technology Wales has published guidance recommending the routine adoption of stereotactic ablative radiotherapy (SABR) to treat people with primary kidney cancer who are not suitable for surgery or other ablative techniques.

SABR delivers precise beams of radiation guided by imaging systems that track the exact three-dimensional location of a tumour.
This allows for high doses of radiation to be delivered to the tumour while minimising damage to health tissue. 

It can delivered in an outpatient setting without the need for general anaesthetic and can be given with fewer treatments than standard radiotherapy. This means that the patient does not usually need to stay in hospital. To read the full HTW guidance click here.